Oculis (OCS) to Release Quarterly Earnings on Thursday

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Oculis (NASDAQ:OCS - Get Free Report) is projected to announce its Q2 2025 results after the market closes on Thursday, August 21st. Analysts expect the company to announce earnings of ($0.53) per share and revenue of $0.1440 million for the quarter. Investors can check the company's upcoming Q2 2025 earningsummary page for the latest details on the call scheduled for Thursday, August 21, 2025 at 4:00 PM ET.

Oculis (NASDAQ:OCS - Get Free Report) last issued its quarterly earnings results on Thursday, August 21st. The company reported ($0.59) EPS for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.06). Oculis had a negative return on equity of 99.12% and a negative net margin of 13,958.12%.The business had revenue of $0.25 million for the quarter, compared to analyst estimates of $0.14 million. On average, analysts expect Oculis to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Oculis Stock Up 0.3%

Shares of OCS stock traded up $0.05 during trading hours on Friday, reaching $17.85. 17,831 shares of the company's stock were exchanged, compared to its average volume of 11,396. The stock has a market capitalization of $779.33 million, a P/E ratio of -6.69 and a beta of 0.27. Oculis has a fifty-two week low of $11.56 and a fifty-two week high of $23.08. The business has a fifty day moving average price of $18.38 and a 200-day moving average price of $18.68.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on OCS. Chardan Capital lifted their price target on shares of Oculis from $28.00 to $33.00 and gave the stock a "buy" rating in a research note on Friday, May 9th. HC Wainwright lifted their price target on shares of Oculis from $32.00 to $33.00 and gave the stock a "buy" rating in a research note on Friday. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $35.67.

Institutional Trading of Oculis

Large investors have recently bought and sold shares of the stock. Bank of America Corp DE grew its position in Oculis by 2.2% in the second quarter. Bank of America Corp DE now owns 40,512 shares of the company's stock valued at $786,000 after acquiring an additional 878 shares during the period. Geode Capital Management LLC grew its holdings in shares of Oculis by 27.7% during the second quarter. Geode Capital Management LLC now owns 29,436 shares of the company's stock worth $571,000 after purchasing an additional 6,384 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Oculis during the second quarter worth $393,000. 22.30% of the stock is currently owned by institutional investors.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.